A1BG

Across TCGA pan-cancer cohorts, A1BG mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of A1BG’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where A1BG mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types A1BG is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where A1BG tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in A1BG mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.354	<.001	12	view →
COAD	Female	II,III,IV	−1.084	<.001	10	view →
LUAD	Female	III,IV	−1.242	<.001	9	view →
LSCC	Male	All	−1.173	<.001	8	view →
PDAC	Male	IV	−1.005	.007	2	view →
OV	All	All	−0.846	.004	2	view →
CCRCC	All	All	+0.241	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

A1BG–HNSC

Open the HNSC breakdown →